Life Sciences Clinical Genomics Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Clinical Genomics Platforms
1.1 - About Life Sciences Clinical Genomics Platforms sector
Companies in the Life Sciences Clinical Genomics Platforms category provide clinical-grade sequencing, data analysis, and interpretation solutions that enable precision diagnostics and treatment decisions. They support end‑to‑end workflows—from sample intake through variant reporting—while meeting regulatory standards. Strategic buyers in clinical genomics look for offerings that improve diagnostic yield, reduce turnaround times, and integrate genomic results into care pathways for oncology, rare disease, and pharmacogenomics programs.
Vendors typically offer NGS testing services and assay panels, validated bioinformatics pipelines for alignment and variant calling, and variant annotation with curated knowledgebases to drive clinical interpretation. Many provide clinical decision support with ACMG/AMP rule engines, report generation, and EHR/LIS integration. Platforms often include sample and workflow management, quality management and audit trails for CLIA/CAP compliance, plus capabilities for germline and somatic testing, pharmacogenomics, and companion diagnostics development.
Primary customers include hospital and reference laboratories, health systems and academic medical centers, and precision medicine programs within biopharma. Outcomes delivered include faster turnaround and scalable workflows, higher diagnostic yield and consistent interpretation, streamlined compliance with CLIA/CAP and data governance, and improved interoperability with EHRs and lab systems. These solutions help operationalize clinical sequencing at scale while supporting evidence-based treatment selection and risk assessment.
2. Buyers in the Life Sciences Clinical Genomics Platforms sector
2.1 Top strategic acquirers of Life Sciences Clinical Genomics Platforms companies
Solid Biosciences
- Description: Provider of gene therapy research and development programs focused on neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia and BAG3 mediated dilated cardiomyopathy, with a mission to attack disease roots and improve daily life for patients.
- Key Products:
- SGT-003: Investigational gene therapy evaluated in the INSPIRE DUCHENNE clinical trial to treat Duchenne muscular dystrophy, aiming to improve outcomes for affected patients
- SGT-501: Novel AAV-based investigational gene therapy granted FDA Fast Track designation for catecholaminergic polymorphic ventricular tachycardia, intended to accelerate development of a first-in-class treatment
- Neuromuscular & Cardiac Pipeline: Research programs developing gene therapies for Friedreich’s ataxia
- BAG3 mediated dilated cardiomyopathy and additional cardiac diseases to address root causes and enhance patients’ daily lives
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Clinical Genomics Platforms sector
M&A buyer group 1: Genomics
Neogen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of food safety and quality assurance solutions for the pet-food sector, offering mycotoxin, pathogen, sanitation and allergen tests, environmental monitoring with microbiome analysis and analytics, plus verification tools, biosecurity, vector control and companion animal health products.
- Key Products:
- Environmental Monitoring Solutions: Provides Salmonella and ATP tests, analytic software, metagenomic microbiome analysis and biosecurity tools to strengthen facility-wide safety programs and enable rapid, data-driven contamination control
- Mycotoxin Testing Kits: Easy-to-use, fast and accurate kits that detect multiple mycotoxins, integrate seamlessly into safety programs and are supported by reference materials, proficiency testing and 24/7 assistance
- Vector Control Solutions: Broad portfolio of rodenticides and insecticides that follow a four-step prevention, identification, execution and monitoring program to eliminate disease-carrying pests in operations
- Companion Animal Health Products: Includes PanaKare Plus supplements for exocrine pancreatic insufficiency and RenaKare potassium supplementation, supporting specific nutritional needs of cats and dogs.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Clinical Genomics Platforms sector
3.1 - Buyout funds in the Life Sciences Clinical Genomics Platforms sector
2.2 - Strategic buyer groups for Life Sciences Clinical Genomics Platforms sector
4 - Top valuation comps for Life Sciences Clinical Genomics Platforms companies
4.2 - Public trading comparable groups for Life Sciences Clinical Genomics Platforms sector
Valuation benchmark group 1: Genomic Sequencing and Diagnostics Companies
Guardant Health
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of blood and tissue tests, data sets, and analytics with a focus on the treatment and management of cancer through precision oncology and advanced research platforms.
- Key Products:
- Guardant360 CDx Test: FDA-approved liquid biopsy test for identifying patients with specific gene mutations to guide treatment decisions
- GuardantOMNI: Liquid biopsy test for comprehensive genomic profiling of tumors in cancer patients
- Shield Test: Blood-based test for colorectal cancer screening
- Guardant Reveal: Blood-only liquid biopsy test for detecting residual and recurrent colorectal cancer
- GuardantINFINITY: High-definition liquid biopsy test for advanced-stage solid tumors.